Loading organizations...
ACX Therapeutics develops precision agriculture technologies, creating sustainable, eco-friendly alternatives to chemical pesticides. The company engineers precision-targeted active compounds designed to disrupt agricultural diseases at their source. This approach diminishes reliance on broad-spectrum chemical inputs, fostering soil health and enhancing resistance management within agricultural ecosystems.
The company was founded in 2024 by Emmanouela Petsolari and Melina Petsolari. Their expertise in biochemistry, biophysics, and computer science provided the foundational insight: leveraging deep scientific understanding for targeted, sustainable solutions to agricultural challenges, moving beyond traditional chemical pesticides. This interdisciplinary background drives their innovative approach.
ACX Therapeutics serves the agricultural sector, offering solutions for farmers and growers seeking resilient and environmentally responsible cultivation methods. Its long-term vision is to enhance the sustainability and resilience of agriculture, better equipping the global food system to meet evolving demands and environmental pressures.
AC+X has 1 tracked investment across 1 company. The latest tracked deal is $12.2M Series B in EVANA AG in June 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 1, 2021 | EVANA AG | $12.2M Series B | Wecken & CIE | Aachener Grundverm, Arventus, Patrizia |